Brief communication on the impact of β-blockers on outcomes in patients receiving cancer immunotherapy
Kennedy, Oliver J Neary, M. T.
Kennedy, Oliver J
Neary, M. T.
Citations
Altmetric:
Abstract
Preclinical studies show that β-adrenergic activation suppresses the immune system and reduces the effectiveness of cancer immunotherapy. As a result, there is considerable interest in using β-blockers (BBs), a cheap and safe class of medication, in combination with immunotherapy to improve outcomes in cancer. This study is a systematic review and meta-analysis of clinical studies. A comprehensive literature search was performed up to May 2022. Studies were included if they reported hazard ratios (HRs) of overall survival (OS), all-cause mortality or progression-free survival (PFS) associated with BBs in patients with solid organ cancer treated with immunotherapy. Study-specific HRs and 95% confidence intervals were pooled in random effects meta-analyses. Nine studies involving over 6350 patients with melanoma, lung, renal, urothelial, or other solid cancers treated with a range of immunotherapies met the inclusion criteria. Across all studies combined, there was no association between concomitant BB use and OS (HR 0.99, 0.83-1.18) or PFS (HR 0.97, 0.89-1.05). In subgroup analyses, BB use made no difference to OS or PFS in melanoma (OS HR 0.66, 0.33-1.34; PFS HR 0.81, 0.62-1.05) or to OS in lung cancer (OS HR 1.00, 0.49-2.07). In summary, this study found no evidence that BBs enhance immunotherapy effectiveness.
Authors
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Article
Citation
Kennedy OJ, Neary MT. Brief Communication on the Impact of β-blockers on Outcomes in Patients Receiving Cancer Immunotherapy. Journal of immunotherapy (Hagerstown, Md : 1997). 2022 Sep 1;45(7):303-6. PubMed PMID: 35947120. Epub 2022/08/11. eng.